Welcome to our dedicated page for ULTRALIFE SEC filings (Ticker: ULBI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ULTRALIFE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ULTRALIFE's regulatory disclosures and financial reporting.
Ultralife Corporation (ULBI) reported an insider share purchase by its President and CEO, who is also a director. On 11/19/2025, the executive bought a total of 2,000 shares of common stock in two open-market transactions. The purchases were made at prices of $4.943 and $4.99 per share, increasing the executive’s direct beneficial ownership to 24,874 shares after the transactions. This filing reflects the executive’s personal investment activity in Ultralife stock.
Ultralife Corporation filed a current report to announce that it has released financial results for its third quarter ended September 30, 2025. The company states that these results are presented in a press release dated November 18, 2025, which is attached as Exhibit 99.1. The filing is signed by the Chief Financial Officer and Treasurer, highlighting that this is the formal disclosure of the latest quarterly performance details through the accompanying press release.
Ultralife Corporation reported higher sales but lower profitability for the quarter ended September 30, 2025. Revenue rose to $43,371 from $35,694, driven mainly by Battery & Energy Products and the contribution from the October 2024 Electrochem acquisition. Gross margin slipped to 22.2% from 24.3%, reflecting less favorable product mix, component quality issues and lower factory throughput, leading to an operating loss of $951 and a net loss attributable to Ultralife of $1,220 versus net income of $258 a year earlier.
For the first nine months of 2025, revenue increased to $142,678 from $120,604, while net income attributable to Ultralife declined to $1,524 from $6,118, as higher interest expense and integration and restructuring costs weighed on results. Electrochem, acquired for $48,022 in cash, contributed nine‑month revenue of $23,718. To fund the deal, Ultralife entered a new credit agreement including a five‑year $55,000 term loan, with $50,937 outstanding at a 6.62% borrowing rate and all debt covenants met. Operating cash flow remained solid at $9,501, lifting cash to $9,260.
Ultralife Corporation filed a Form 12b-25 (NT 10-Q) notifying a late filing for its quarterly report for the period ended September 30, 2025. The company cites its integration of Electrochem Solutions, Inc.—acquired from Integer Holdings on October 31, 2024—as the cause, noting that Electrochem’s books and records transitioned from Integer’s systems to Ultralife’s during the third quarter of 2025.
Ultralife states it needs additional time to finalize third quarter results and allow its independent accountants to complete their review without unreasonable effort or expense. The company expects to file the Form 10-Q within the five-day extension under Rule 12b-25, no later than November 17, 2025.
Ultralife Corporation replaced its independent auditor on August 22, 2025, when the Audit and Finance Committee approved ending the engagement with Freed Maxick P.C. and engaged Withum Smith+Brown, PC effective immediately due to Withum's acquisition of certain assets of Freed Maxick. Freed Maxick's audit reports for the years ended December 31, 2023 and December 31, 2024 contained no qualifications on the company’s financial statements, but its report on internal control over financial reporting for 2024 stated the company did not maintain effective internal control because of a material weakness. The company reported no disagreements or reportable events with Freed Maxick for the reviewed periods and furnished Freed Maxick a copy of this disclosure; Freed Maxick provided a letter dated August 25, 2025 responding to the disclosure.
ULTRALIFE CORP director and 10% owner Bradford T. Whitmore reported indirect open-market purchases of the company’s common stock. Through Whitmore Holdings, LLC, he bought a total of 58,664 shares between August 19 and 21, 2025 at weighted average prices around $6.56–$6.63 per share, bringing Whitmore Holdings’ position to 1,128,731 shares.
The filing also lists other holdings associated with him, including 205,915 shares held directly, 4,452,283 shares held by Sunray I, LLC, and 518,616 shares held by Grace Brothers, LP, where he is described as an indirect beneficial owner.